SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of ‘SNB-101’

SEONGNAM, South Korea, May 15, 2026 /PRNewswire/ -- SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a... The post SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of ‘SNB-101’ appeared first on Kosmo Digital .

Go to News Site